WO2018166298A1 - Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use - Google Patents
Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use Download PDFInfo
- Publication number
- WO2018166298A1 WO2018166298A1 PCT/CN2018/073916 CN2018073916W WO2018166298A1 WO 2018166298 A1 WO2018166298 A1 WO 2018166298A1 CN 2018073916 W CN2018073916 W CN 2018073916W WO 2018166298 A1 WO2018166298 A1 WO 2018166298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- vaccine
- csf
- pharmaceutical composition
- immune
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 108
- 230000001024 immunotherapeutic effect Effects 0.000 title claims abstract description 106
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000000091 immunopotentiator Effects 0.000 title description 2
- 108091007433 antigens Proteins 0.000 claims abstract description 316
- 102000036639 antigens Human genes 0.000 claims abstract description 316
- 239000000427 antigen Substances 0.000 claims abstract description 300
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 228
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims abstract description 228
- 239000003623 enhancer Substances 0.000 claims abstract description 46
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 102000014150 Interferons Human genes 0.000 claims abstract description 33
- 108010050904 Interferons Proteins 0.000 claims abstract description 33
- 229940079322 interferon Drugs 0.000 claims abstract description 33
- 241000700605 Viruses Species 0.000 claims abstract description 29
- 102000006992 Interferon-alpha Human genes 0.000 claims description 117
- 108010047761 Interferon-alpha Proteins 0.000 claims description 117
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 57
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 57
- 210000004027 cell Anatomy 0.000 claims description 56
- 208000002672 hepatitis B Diseases 0.000 claims description 56
- 210000001616 monocyte Anatomy 0.000 claims description 56
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 30
- 230000009385 viral infection Effects 0.000 claims description 28
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 230000028993 immune response Effects 0.000 claims description 25
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 24
- 239000007924 injection Substances 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 18
- 230000006058 immune tolerance Effects 0.000 claims description 18
- 230000007969 cellular immunity Effects 0.000 claims description 17
- 210000000716 merkel cell Anatomy 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 17
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims description 16
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 14
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 14
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 230000005975 antitumor immune response Effects 0.000 claims description 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 13
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 230000006870 function Effects 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 239000000969 carrier Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 230000004727 humoral immunity Effects 0.000 claims description 8
- 229940031626 subunit vaccine Drugs 0.000 claims description 8
- 241001529453 unidentified herpesvirus Species 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 241000194017 Streptococcus Species 0.000 claims description 7
- 229940031567 attenuated vaccine Drugs 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 230000004069 differentiation Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940031551 inactivated vaccine Drugs 0.000 claims description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 210000003494 hepatocyte Anatomy 0.000 claims description 5
- 244000045947 parasite Species 0.000 claims description 5
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000001461 cytolytic effect Effects 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 3
- 230000036436 anti-hiv Effects 0.000 claims description 3
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 101710142246 External core antigen Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 45
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 241000894006 Bacteria Species 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 229960005486 vaccine Drugs 0.000 description 213
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 123
- 239000002671 adjuvant Substances 0.000 description 76
- 230000003053 immunization Effects 0.000 description 76
- 238000002649 immunization Methods 0.000 description 76
- 241000699670 Mus sp. Species 0.000 description 69
- 239000000203 mixture Substances 0.000 description 62
- 241000700721 Hepatitis B virus Species 0.000 description 53
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 47
- 230000005951 type IV hypersensitivity Effects 0.000 description 47
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 47
- 210000002966 serum Anatomy 0.000 description 46
- 230000000694 effects Effects 0.000 description 44
- 210000004443 dendritic cell Anatomy 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 35
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 27
- 229910052782 aluminium Inorganic materials 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000011725 BALB/c mouse Methods 0.000 description 20
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 19
- 229940037003 alum Drugs 0.000 description 17
- 210000005259 peripheral blood Anatomy 0.000 description 17
- 239000011886 peripheral blood Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000024932 T cell mediated immunity Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 15
- 230000008961 swelling Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 230000001900 immune effect Effects 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 229940021747 therapeutic vaccine Drugs 0.000 description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 10
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 101710132601 Capsid protein Proteins 0.000 description 10
- 238000012286 ELISA Assay Methods 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 108010088751 Albumins Proteins 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000008349 antigen-specific humoral response Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000012888 bovine serum Substances 0.000 description 9
- 230000016784 immunoglobulin production Effects 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 8
- 102000013462 Interleukin-12 Human genes 0.000 description 8
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 8
- 238000010353 genetic engineering Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 229940023041 peptide vaccine Drugs 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 6
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 6
- 208000037581 Persistent Infection Diseases 0.000 description 6
- 230000006052 T cell proliferation Effects 0.000 description 6
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000036755 cellular response Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 5
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000009169 immunotherapy Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical group O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 230000005934 immune activation Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229950000038 interferon alfa Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- KQNZDYYTLMIZCT-KFKPYADVSA-N (2e,7s,10e,12r,13r,15s)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\C2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KFKPYADVSA-N 0.000 description 2
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000013388 immunohistochemistry analysis Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- -1 wetting Substances 0.000 description 2
- 241000701242 Adenoviridae Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
- 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000579048 Merkel cell polyomavirus Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001135902 Peanut clump virus Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229940124840 Streptococcal vaccine Drugs 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000005208 blood dendritic cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- JGPOSNWWINVNFV-UHFFFAOYSA-N carboxyfluorescein diacetate succinimidyl ester Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O JGPOSNWWINVNFV-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940039286 hepatocellular carcinoma vaccine Drugs 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000002074 inflammatory monocyte Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- MZEOSVPWMSEFPW-XYCDVDSTSA-N n-[2-[[(3s,4s)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound N([C@H]1CN(C[C@@H]1OCC)C1CCC(O)(CC1)C=1C=C2OCOC2=CC=1)C(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 MZEOSVPWMSEFPW-XYCDVDSTSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/836—Intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/844—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Gourp (n=5) | |
|
① PBS | - | |
② GM- | 10μg | |
③ IFN- |
10000 |
|
④ | 1μg | |
⑤ GM-CSF/IFN-α | 10μg/ |
|
⑥ GM-CSF/VACCINE | 10μg/ |
|
⑦ IFN-α/VACCINE | 10000IU/ |
|
⑧ GM-CSF/IFN-α/VACCINE | 10μg/10000IU/ |
|
⑨ 3×GM-CSF+VACCINE | 10μg (one day one time, a total of three times) +1μg |
Claims (33)
- An immune enhancer comprising at least a recombinant interferon and a granulocyte-macrophage colony-stimulating factor.
- The immune enhancer of claim 1, wherein the ratio of the content of the recombinant interferon to the content of the recombinant granulocyte-macrophage colony-stimulating factor is (about 0.1 × 10 4 IU -about 5 × 10 6 IU) to (about 1μg-about 200μg) .
- The immune enhancers of claim 1, wherein the ratio of the content of the recombinant interferon to the content of the recombinant granulocyte-macrophage colony-stimulating factor is (about 0.5× 10 4 IU -about 1× 10 5 IU) to (about 5μg -about 50μg) .
- The immune enhancers of claim 1 and claim 3, wherein the recombinant interferon is interferon alpha.
- An immunotherapeutic pharmaceutical composition comprises at least an antigen and an immune enhancer of claims 1-4.
- The immunotherapeutic pharmaceutical composition of claim 5, wherein the recombinant interferon is interferon alpha-2a.
- The immunotherapeutic pharmaceutical composition of claim 5, wherein the antigen comprises a recombinant protein antigen.
- The immunotherapeutic pharmaceutical composition of claim 5, wherein the ratio of the content of the recombinant interferon to the content of the recombinant granulocyte-macrophage colony-stimulating factor is (about 0.5× 10 4 IU -about1 ×10 5 IU) to (about 5μg -about 20μg) .
- The immunotherapeutic pharmaceutical composition of claim 5, wherein the ratio of the content of the recombinant interferon to the content of the recombinant granulocyte-macrophage colony-stimulating factor is about 1 × 10 4 IU to about 10μg.
- The immunotherapeutic pharmaceutical composition of claim 7, wherein the recombinant protein antigen is at least one of a viral antigen, a bacterial antigen, a fungal antigen, a parasite antigen, and a tumor antigen.
- The immunotherapeutic pharmaceutical composition of claim 10, wherein the viral antigen is at least one of HBV antigens, herpesvirus antigens, HPV antigens, HIV antigens, Merkel cell virus antigens, influenza antigens and RSV antigens.
- The immunotherapeutic pharmaceutical composition of claim 7, wherein the recombinant protein antigen is an inactivated vaccine antigen, an attenuated vaccine antigen or a subunit vaccine antigen.
- The immunotherapeutic pharmaceutical composition of claim 7, wherein the recombinant protein antigen is a genetically engineered recombinant antigen.
- The immunotherapeutic pharmaceutical composition of claim 5, wherein the immunotherapeutic pharmaceutical composition further comprises pharmaceutically or immunologically acceptable carriers or excipients.
- A method for preparing the immunotherapeutic pharmaceutical composition of claim 5, wherein the method comprises the steps of:mixing the antigen, the recombinant interferon, the granulocyte-macrophage colony-stimulating factor, and the pharmaceutically or immunologically acceptable carriers or excipients under aseptic conditions to produce the immunotherapeutic pharmaceutical composition.
- A use of the immune enhancer of claims 1 to 3, wherein the use comprises administering to a subject a safe and therapeutically effective amount of the Immune enhancer either before the administration of the antigen or during the administration of the antigen (s) to the subject.
- The use of claim 16, wherein the administration comprises at least mucosal administration or injection administration.
- The use of claim 16, wherein the subject is a mammal.
- The use of the immunotherapeutic pharmaceutical compositions of claim 5 in the preparation of immunotherapeutic drugs, the use comprising:1) promoting monocytes production;2) promoting expression of monocyte CCR2;3) promoting differentiation of Ly6C hiCCR2 + monocytes into DCs with phenotype CD11b + CD11c +;4) improving the cellular immunity and CTL cytolytic functions of a subject;5) promoting the humoral immunity of the subject and production of one or several protective antibodies.
- The use of claim 19, wherein the use comprises preventing or treating one or more of viral infections, bacterial infections, fungal infections, parasitic infections, and tumors.
- The use of claim 20, wherein the viral infections comprise one or more of human hepatitis virus infection, herpes virus infection, human papilloma virus infection, human immunodeficiency virus infection, Merkel cell virus infection, influenza virus infection and respiratory syncytium virus infection.
- The use of claim 20, wherein the viral infection is chronic hepatitis B.
- The use of claim 19, wherein the antigen is a hepatitis B surface antigen and the immunotherapeutic pharmaceutical composition can break down the immune tolerance and eliminate infected hepatocytes, HBeAg and HBsAg, while generating anti-HBs Ab.
- The use of claim 19, wherein the antigen is a tumor antigen and the immunotherapeutic pharmaceutical composition induces an anti-tumor immune response.
- The use of claim 24, wherein the tumor antigen comprises at least one of a prostate cancer antigen polypeptide or epitopic peptide, a breast cancer antigen polypeptide or epitopic peptide, a colorectal cancer antigen polypeptide or epitopic peptide, a cervical cancer polypeptide or epitopic peptide, a liver cancer polypeptide or epitopic peptide, multiple myeloma polypeptide or epitopic peptide, and renal cell carcinoma polypeptide or epitopic peptide.
- The use of claim 19, wherein the antigen is one of the streptococcal antigens and the immunotherapeutic pharmaceutical composition induces an immune response that produces an antibacterial infection.
- The use of claim 26, wherein the streptococcal antigen is a modified Streptococcus Type A epitope peptide.
- The use of claim 19, wherein the antigen is one of HIV antigens and the immunotherapeutic pharmaceutical composition induces an immune response that produces an anti-HIV infection.
- The use of claim 28, wherein the HIV antigen is an HIV epitope peptide.
- The use of claim 19, wherein the antigen is one of Merkel cell viral antigens and the immunotherapeutic pharmaceutical composition induces an immune response that produces an anti-Merkel cell viral infection.
- The use of claim 30, wherein the Merkel cell viral antigen is one of the Merkel cell polypeptides.
- Any use of claims 19-31, wherein the use comprises administration of a safe and therapeutically effective amount of the immunotherapeutic pharmaceutical composition to a subject to be immunized.
- The use of claim 30, wherein the subject is a mammal.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019550155A JP7271433B2 (en) | 2017-03-13 | 2018-01-24 | Immunostimulants, immunotherapeutic pharmaceutical compositions, and their preparation and use |
US16/491,550 US11771759B2 (en) | 2017-03-13 | 2018-01-24 | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
AU2018233208A AU2018233208A1 (en) | 2017-03-13 | 2018-01-24 | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
KR1020197026852A KR20190122717A (en) | 2017-03-13 | 2018-01-24 | Immune enhancers, immunotherapeutic pharmaceutical compositions and their preparation and use |
EP18768314.9A EP3595714A4 (en) | 2017-03-13 | 2018-01-24 | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710021679.6 | 2017-03-13 | ||
CN201710021679 | 2017-03-13 | ||
CN201810035029.1 | 2018-01-15 | ||
CN201810035029.1A CN108567977B (en) | 2017-03-13 | 2018-01-15 | Immunopotentiator, immunotherapy pharmaceutical composition, preparation and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018166298A1 true WO2018166298A1 (en) | 2018-09-20 |
Family
ID=63522747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/073916 WO2018166298A1 (en) | 2017-03-13 | 2018-01-24 | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018166298A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3986459A4 (en) * | 2019-06-21 | 2023-07-26 | Variation Biotechnologies Inc. | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b |
WO2023142176A1 (en) * | 2022-01-30 | 2023-08-03 | 山东农业大学 | Pharmaceutical composition for intravenous injection, preparation containing same, and preparation method therefor and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101355928A (en) * | 2005-04-26 | 2009-01-28 | 卫材R&D管理株式会社 | Compositions and methods for cancer immunotherapy |
CN101748151A (en) * | 2008-12-19 | 2010-06-23 | 深圳市源兴生物医药科技有限公司 | Recombinant human hepatitis C virus antigen adenoviral vector and applications thereof |
CN103772508A (en) * | 2014-01-15 | 2014-05-07 | 南京勉益生物药业有限公司 | Therapeutic vaccine for immune-enhanced human papilloma virus infection and related diseases |
CN104338132A (en) * | 2013-07-26 | 2015-02-11 | 复旦大学 | Viral immunotherapy drug compound and purpose thereof |
-
2018
- 2018-01-24 WO PCT/CN2018/073916 patent/WO2018166298A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101355928A (en) * | 2005-04-26 | 2009-01-28 | 卫材R&D管理株式会社 | Compositions and methods for cancer immunotherapy |
CN101748151A (en) * | 2008-12-19 | 2010-06-23 | 深圳市源兴生物医药科技有限公司 | Recombinant human hepatitis C virus antigen adenoviral vector and applications thereof |
CN104338132A (en) * | 2013-07-26 | 2015-02-11 | 复旦大学 | Viral immunotherapy drug compound and purpose thereof |
CN103772508A (en) * | 2014-01-15 | 2014-05-07 | 南京勉益生物药业有限公司 | Therapeutic vaccine for immune-enhanced human papilloma virus infection and related diseases |
Non-Patent Citations (1)
Title |
---|
See also references of EP3595714A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3986459A4 (en) * | 2019-06-21 | 2023-07-26 | Variation Biotechnologies Inc. | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b |
WO2023142176A1 (en) * | 2022-01-30 | 2023-08-03 | 山东农业大学 | Pharmaceutical composition for intravenous injection, preparation containing same, and preparation method therefor and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9987352B2 (en) | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection | |
JP6109989B2 (en) | Yeast-based therapeutics for chronic hepatitis B infection | |
Hunter et al. | Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha | |
US8445663B2 (en) | Compositions and methods that enhance an immune response | |
JP6629195B2 (en) | Pharmaceutical compositions for viral immunotherapy and uses thereof | |
US11771759B2 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
WO2018166298A1 (en) | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use | |
CN107693788B (en) | Pharmaceutical composition for preventing or treating hepatitis B and application thereof | |
US20230310591A1 (en) | Vaccine Boost Methods and Compositions | |
EP1676587A1 (en) | Pharmaceutical compositions for therapeutic use | |
QU et al. | Effect of Plasmid DNA on Immunogenicity of HBsAg–Anti-HBs Complex | |
NZ619761B2 (en) | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection | |
OA16792A (en) | Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection. | |
JPWO2006080420A1 (en) | Antigen-specific T cell inducer, antibody production inducer, immune enhancer, and vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18768314 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018233208 Country of ref document: AU Date of ref document: 20180124 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197026852 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019550155 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018768314 Country of ref document: EP Effective date: 20191014 |